TriangleINCB123667 (NCT07023627)
INCB123667 trial for Ovarian Cancer (NCT07023627). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for women aged 18–99 with platinum-resistant high-grade serous ovarian, fallopian-tube or peritoneal cancer and cyclin E1 overexpression, after one to four treatment lines. Prior bevacizumab and, for FRα-positive tumors, mirvetuximab are required unless medically unsuitable.
The idea: oral INCB123667 blocks CDK2, a cell-division regulator. Twice-daily treatment is assigned by cyclin E1 expression; researchers measure tumor responses. Primary platinum-refractory disease is excluded. Tissue testing is required; suitable stored samples can replace fresh biopsy.
This phase 2 study plans 160 patients. Incyte sponsors it; 38 US sites are recruiting, including Mobile.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.